HK18695A - Inhalation medicaments for treating respiratory disorders - Google Patents

Inhalation medicaments for treating respiratory disorders Download PDF

Info

Publication number
HK18695A
HK18695A HK18695A HK18695A HK18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A HK 18695 A HK18695 A HK 18695A
Authority
HK
Hong Kong
Prior art keywords
respiratory disorders
treating respiratory
inhalation medicaments
inhalation
medicaments
Prior art date
Application number
HK18695A
Other languages
English (en)
Inventor
Barry Douglas Palmer James
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK18695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK18695A publication Critical patent/HK18695A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HK18695A 1989-09-08 1995-02-09 Inhalation medicaments for treating respiratory disorders HK18695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
HK18695A true HK18695A (en) 1995-02-17

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18695A HK18695A (en) 1989-09-08 1995-02-09 Inhalation medicaments for treating respiratory disorders

Country Status (20)

Country Link
EP (1) EP0416951B1 (2)
JP (1) JP3042867B2 (2)
AT (1) ATE99941T1 (2)
BE (1) BE1003053A3 (2)
CA (1) CA2024916C (2)
CH (1) CH680983C9 (2)
DE (2) DE69005951T2 (2)
DK (1) DK0416951T3 (2)
ES (1) ES2062392T3 (2)
FR (1) FR2651677B1 (2)
HK (1) HK18695A (2)
HU (1) HU211272A9 (2)
IE (1) IE65535B1 (2)
IL (1) IL95590A (2)
IT (1) IT1241996B (2)
LU (1) LU90392I2 (2)
NL (1) NL990012I2 (2)
NZ (1) NZ235221A (2)
PH (1) PH27594A (2)
SG (1) SG166294G (2)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ES2172510T3 (es) * 1991-12-18 2002-10-01 Astrazeneca Ab Nueva combinacion de formoterol y budesonida.
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
AU7026800A (en) 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
WO2002012266A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
ATE396716T1 (de) 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
WO2003074469A1 (de) * 2002-03-04 2003-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue zimtsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
ES2471139T3 (es) 2003-08-06 2014-06-25 Galephar M/F Combinaciones ventajosas para la inhalaci�n de nacistelina y broncodilatadores
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
PT1616592E (pt) 2004-07-16 2010-12-10 Almirall Sa Inalador para administração de fármacos em pó e um cartucho de pó para utilização com este inalador
EP2063940B1 (en) 2006-12-22 2012-01-11 Almirall, S.A. Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
JP3042867B2 (ja) 2000-05-22
PH27594A (en) 1993-08-31
DK0416951T3 (da) 1994-02-14
BE1003053A3 (fr) 1991-11-05
FR2651677A1 (fr) 1991-03-15
EP0416951B1 (en) 1994-01-12
ATE99941T1 (de) 1994-01-15
IL95590A (en) 1996-06-18
NZ235221A (en) 1992-11-25
DE69005951T2 (de) 1994-05-26
HU211272A9 (en) 1995-11-28
NL990012I2 (nl) 1999-09-01
JPH03167120A (ja) 1991-07-19
IE65535B1 (en) 1995-11-01
IE903256A1 (en) 1991-03-13
CA2024916A1 (en) 1991-03-09
CH680983A5 (2) 1992-12-31
IT1241996B (it) 1994-02-02
CH680983C9 (2) 2008-08-15
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
CH680983C1 (2) 2008-06-25
FR2651677B1 (fr) 1993-08-06
LU90392I2 (fr) 1999-06-28
IT9048260A0 (it) 1990-09-07
DE19975040I2 (de) 2006-07-13
SG166294G (en) 1995-06-16
EP0416951A1 (en) 1991-03-13
DE69005951D1 (de) 1994-02-24
NL990012I1 (nl) 1999-07-01
CA2024916C (en) 2002-07-09
IL95590A0 (en) 1991-09-16

Similar Documents

Publication Publication Date Title
HK18695A (en) Inhalation medicaments for treating respiratory disorders
GB2235626B (en) Inhalation medicaments for treating respiratory disorders
CA2123909A1 (en) New combination of formoterol and budesonide
GEP20002253B (en) Pharmaceutical Aerosol Formulation, Proportioning Inhalator and Method for Treatment of Respiratory Diseases
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
GB9425160D0 (en) Medicaments
CA2125666A1 (en) Medicaments
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
GB9103764D0 (en) Compositions
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
AU3598299A (en) Improved compositions for inhalation
MY111155A (en) Medicaments
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
CA2321265A1 (en) Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070907